Strategic Partnering Opportunities

Concert Pharmaceuticals is applying its platform technology in deuterium chemistry to develop novel and differentiated small molecule patentable drugs. Concert has a broad pipeline of proprietary drug candidates in the areas of diabetic nephropathy, pain/spasticity, epilepsy, oncology, GI motility, HIV, infectious disease (MRSA, HCV, other), among others. Concert’s business strategy is to utilize collaborative pharmaceutical partnerships to drive these new chemical entities through development and commercialization to address unmet medical needs.

For further information please contact: Greg Miller Vice President, Business and Corporate Development 781.674.5227 BD@concertpharma.com

E-Newsletter Subscribe to Concert's quarterly business development newsletter to receive R&D updates, corporate news and more via e-mail. Sign up for our BD Newsletter

Corporate Materials

• Fact Sheet: Deuterated Chemical Entity (DCE) Platform
• Publication: Innovations in Pharmaceutical Technology, "The Development of Deuterium Containing Drugs"
• Publication: Drug Discovery & Development: Chemistry for Drug Development: Deuterium Modification
• Concert's scientific poster presentations are available upon request
• U.S. Issued Patents
  

Upcoming Events

There are currently no upcoming events

[ back to top ]